Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541531 | 0.93 | CXCR4 (0.34) | CXCR4GSK3AGSK3BHDAC3HDAC1 | |
| SCHEMBL541614 | 0.92 | CXCR4 (0.34) | CXCR4GSK3AGSK3BHDAC3HDAC1 | |
| SCHEMBL541547 | 0.91 | CXCR4 (0.36) | CXCR4GSK3AGSK3BHDAC3HDAC1 | |
| SCHEMBL541918 | 0.90 | GSK3A (0.43) | CXCR4GSK3AGSK3BHDAC3HDAC1 | |
| SCHEMBL6521503 | 0.89 | HDAC3 (0.41) | CXCR4GSK3AGSK3BHDAC3HDAC1 | |
| SCHEMBL541242 | 0.86 | CXCR4 (0.38) | CXCR4GSK3AGSK3BHDAC3HDAC1 | |
| SCHEMBL15397177 | 0.85 | CXCR4 (0.34) | CXCR4HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL541615 | 0.85 | CXCR4 (0.34) | CXCR4GSK3AGSK3BHDAC3HDAC1 | |
| SCHEMBL541548 | 0.84 | CXCR4 (0.36) | CXCR4GSK3AGSK3BHDAC3HDAC1 | |
| SCHEMBL541926 | 0.84 | CXCR4 (0.37) | CXCR4HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | CXCR4 350/4885GSK3A 4502/4885GSK3B 4534/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | CXCR4 206/4885GSK3A 4281/4885GSK3B 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.